Taysha Gene Therapies, Inc. (TSHA) Earnings Call Transcripts
Taysha Gene Therapies, Inc.'s Latest Earnings Call - June 22, 2026
In the second quarter of 2026, Taysha Gene Therapies provided a significant update on its TSHA-102 program for Rett syndrome, which could be a major catalyst for the stock. The company announced the completion of dosing in the REVEAL pivotal trial and reported a 100% response rate in the Part A data, with all 12 patients achieving at least one developmental milestone. Management maintained its guidance for a potential BLA submission based on a 6-month interim analysis in early 2027, emphasizing the strong market opportunity with an estimated 15,000 to 20,000 patients in the U.S., EU, and U.K.
Reported metrics
| Metric | Value |
|---|---|
| Response Rate in Part A | 100% (beat) |
| Developmental Milestones Increase | 69% increase (positive) |
| Total Functional Gains | 310 gains (positive) |
| Safety Events | 0 serious adverse events (positive) |
| Market Size | 15,000 to 20,000 patients (positive) |
| Enrollment in REVEAL Trial | 17 patients (positive) |
Guidance from management
Management maintained guidance for a potential BLA submission based on the 6-month interim analysis in early 2027, indicating confidence in the data collected thus far.
What management said
Yes. I'll take the first question. I can tell you the vast majority of patients were dosed before the end of May. There was a couple of patients in June. And we've obviously, at this point in time, dosed 29 patients with TSHA-102 and the safety profile continues to look very, very encouraging. Suku, I don't know more to add about the second part of Maurice question there.
Yes. And Sean, I was also going to add for your benefit, Jack, that given the broad significant clinical efficacy that we've seen in Part A, we have fairly good power and a p-value for regulatory standards now set up for Part B. So essentially, by -- so I guess my point is the statistical one that when you have broad clinical separation between an intervention and the comparator [ there ], which is the plateau Phas...
What analysts pressed on
Analysts expressed concerns regarding the long-term durability of treatment effects and the potential for treatment-related adverse events as more patients are treated. There were inquiries about the impact of additional supportive therapies on milestone gains and how the company plans to manage demand versus patient safety during the rollout.
Main topics on the call
- Completion of REVEAL Pivotal Trial Dosing — Taysha announced the completion of dosing in the REVEAL pivotal trial with 17 patients treated. This milestone is crucial as it sets the stage for the upcoming interim analysis, which could support a BLA submission.
- Strong Efficacy Data from Part A — The Part A data showed a 100% response rate, with all 12 patients achieving one or more developmental milestones. Management stated, "We observed a rapid and robust response, supporting the pivotal trial is well powered ...
- Durability of Treatment Effects — Management highlighted that the treatment effects deepen over time, with developmental milestones increasing by 69% from 6 to 12 months and by 94% from 6 months to beyond 12 months. This durability is critical for long-t...
- Safety Profile of TSHA-102 — TSHA-102 continues to be well tolerated, with no treatment-related serious adverse events reported. Management noted, "We are pleased to report that across the 29 patients treated... there have been no treatment-related ...
Read the full Taysha Gene Therapies, Inc. transcript (June 22, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. (TSHA) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 41 calls on record spanning March 3, 2021 to June 22, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 41 Taysha Gene Therapies, Inc. earnings call transcripts on record, spanning March 3, 2021 to June 22, 2026. Based on this history, Taysha Gene Therapies, Inc. reports quarterly. The most recent call on file is dated June 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- TSHA
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 41
- First call
- March 3, 2021
- Most recent
- June 22, 2026
- Reporting cadence
- quarterly